HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C)
丙型肝炎抗病毒长期治疗以预防肝硬化 (HALT-C)
基本信息
- 批准号:7719421
- 负责人:
- 金额:$ 1.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffectAntiviral AgentsBloodBlood specimenChronic Hepatitis CCirrhosisClinic VisitsCoinComputer Retrieval of Information on Scientific Projects DatabaseEnrollmentEsophagusFundingGrantHemorrhageHepatitisHepatitis CInjection of therapeutic agentInstitutionInterferonsMaintenanceMaintenance TherapyMalignant neoplasm of liverPatientsPharmaceutical PreparationsPhaseProceduresQuality of lifeQuestionnairesRecording of previous eventsResearchResearch PersonnelResourcesRibavirinRiskScreening procedureSourceStandards of Weights and MeasuresStomachStreamUnited StatesUnited States Food and Drug AdministrationUnited States National Institutes of HealthVaricosityVeinsViralVisitWeekfollow-upliver biopsyprevent
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Hepatitis C affects about 4 million people in the United States and leads to cirrhosis and liver cancer after many years, in some patients. Treatment with interferon, alone or in combination with a second anti-viral agent ribavirin has been approved by the Food and Drug Administration and is now considered standard therapy for chronic hepatitis C. A slow release form of interferon, called PEG-interferon, remains in the blood stream for one week and gives better results than interferon alone, with fewer injections required. The present study is aimed at patients who have received previous treatment and failed to clear hepatitis C. Patients who meet entry criteria, and are enrolled in the trial, will first be treated with the combination of PEG Interferon plus ribavirin. Responders to this treatment will be given a full one year of therapy. Nonresponders, after 24 weeks of the combination treatment, will be entered into the study of maintenance therapy. Nonresponders will be evenly assigned (by a procedure similar to the toss of a coin) to either maintenance with PEG Interferon (treatment) or no treatment (observation). Follow-up will be identical for the treatment and observation groups and will require 3-monthly visits for 3 1/2 years with 6 months follow-up. Each visit will include history, exam, quality-of-life questionnaire, and blood drawing. Liver biopsies will be performed at two and four years following start of the initial phase. Some patients will undergo endoscopic examination of the esophagus and stomach for varices, large veins at risk for bleed. Risks encountered may include side effects of study medications, that involved in obtaining blood samples, and that of liver biopsy at year 2 and at end of study. Patients will be required to attend two screening visits, plus clinic visits at routine intervals over the entire course of the study.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
在美国,丙型肝炎影响着大约400万人,并在许多年后导致肝硬变和肝癌,在一些患者中。单独使用干扰素或与第二种抗病毒药物利巴韦林联合治疗已获美国食品和药物管理局批准,现在被认为是慢性丙型肝炎的标准治疗方法。一种名为聚乙二醇干扰素的缓释干扰素在血液中保留一周,比单独使用干扰素效果更好,所需注射更少。本研究的目标是那些以前接受过治疗但未能清除丙型肝炎的患者。符合入选标准并参加试验的患者将首先接受聚乙二醇干扰素和利巴韦林的联合治疗。这种治疗的应答者将接受整整一年的治疗。在联合治疗24周后,无应答者将进入维持治疗研究。无反应者将被平均分配(通过类似于掷硬币的程序),要么接受聚乙二醇干扰素(治疗)维持治疗,要么不接受治疗(观察)。治疗组和观察组的随访将是相同的,需要3个月的随访,为期3年半,6个月的随访。每次访问将包括历史、考试、生活质量问卷和抽血。肝活检将在初始阶段开始后的两年和四年进行。一些患者将接受食道和胃的内窥镜检查,看是否有静脉曲张,大静脉有出血的风险。遇到的风险可能包括研究药物的副作用,包括获取血液样本的副作用,以及在第二年和研究结束时进行肝活检的副作用。患者将被要求参加两次筛查访问,以及在整个研究过程中定期进行诊所访问。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory Thomas Everson其他文献
Gregory Thomas Everson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory Thomas Everson', 18)}}的其他基金
Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL)
成人至成人活体肝移植队列研究 (A2ALL)
- 批准号:
8015117 - 财政年份:2010
- 资助金额:
$ 1.78万 - 项目类别:
A2ALL LADR PROTOCOL:PRE-TRNSPLNT TRTMNT TO PRVNT RCURRNCE OF HEPC AFT LVR TRNSPL
A2ALL LADR 协议:PRE-TRNSPLNT TRTMNT 到 HEPC AFT LVR TRNSPL 的 PRVNT 复发
- 批准号:
7719478 - 财政年份:2008
- 资助金额:
$ 1.78万 - 项目类别:
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC HCV (QLFT)
慢性丙型肝炎肝功能的定量评估 (QLFT)
- 批准号:
7719422 - 财政年份:2008
- 资助金额:
$ 1.78万 - 项目类别:
RESTORATION OF HEPATIC FUNCTION IN LIVING LIVER DONORS (ANCILLARY STUDY OF A2ALL
活体肝捐献者肝功能的恢复(A2ALL 的辅助研究
- 批准号:
7719472 - 财政年份:2008
- 资助金额:
$ 1.78万 - 项目类别:
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC HCV (QLFT)
慢性丙型肝炎肝功能的定量评估 (QLFT)
- 批准号:
7604372 - 财政年份:2007
- 资助金额:
$ 1.78万 - 项目类别:
RESTORATION OF HEPATIC FUNCTION IN LIVING LIVER DONORS (ANCILLARY STUDY OF A2ALL
活体肝捐献者肝功能的恢复(A2ALL 的辅助研究
- 批准号:
7604422 - 财政年份:2007
- 资助金额:
$ 1.78万 - 项目类别:
A2ALL LADR PROTOCOL:PRE-TRNSPLNT TRTMNT TO PRVNT RCURRNCE OF HEPC AFT LVR TRNSPL
A2ALL LADR 协议:PRE-TRNSPLNT TRTMNT 到 HEPC AFT LVR TRNSPL 的 PRVNT 复发
- 批准号:
7604428 - 财政年份:2007
- 资助金额:
$ 1.78万 - 项目类别:
HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C)
丙型肝炎抗病毒长期治疗以预防肝硬化 (HALT-C)
- 批准号:
7604371 - 财政年份:2007
- 资助金额:
$ 1.78万 - 项目类别:
A2ALL LADR PROTOCOL:PRE-TRNSPLNT TRTMNT TO PRVNT RCURRNCE OF HEPC AFT LVR TRNSPL
A2ALL LADR 协议:PRE-TRNSPLNT TRTMNT 到 HEPC AFT LVR TRNSPL 的 PRVNT 复发
- 批准号:
7377842 - 财政年份:2006
- 资助金额:
$ 1.78万 - 项目类别:
HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C)
丙型肝炎抗病毒长期治疗以预防肝硬化 (HALT-C)
- 批准号:
7377765 - 财政年份:2006
- 资助金额:
$ 1.78万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 1.78万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 1.78万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 1.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists